← Back

Wire · operational-macro

FDA Approves Generic Binimetinib for BRAF-Mutant Melanoma and NSCLC

Published

16 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at oncnursingnews.com →

◆ Verified

Fusion42 · 16 November 2026 · Fusion42 review

The FDA has granted final approval to Alembic Pharmaceuticals' generic binimetinib tablets in 15 mg and 45 mg strengths for BRAF-mutant melanoma and NSCLC, including a new higher dose option. Alembic is eligible for 180 days of generic exclusivity, potentially impacting market access and pricing of the reference drug Mektovi.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 16 Nov 2026 and 17 Nov 2026.

◆ ◆ The Wire takeaway

You face new competition from a generic with a novel 45 mg dose that could reorder melanoma and NSCLC treatment choices. Check your supply chains and pricing assumptions now as drug buyers gain more options.

◆ Coverage

2 sources · first reported 16 Nov 2026 · latest 17 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalgeneric-drugsoncologybraf-mutationpharma-exclusivity